Journal of the Society for Gynecologic Investigation

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

http://mc.manuscriptcentral.com/rsci

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker, C. L.
Right arrow Articles by Fuchs-Young, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, C. L.
Right arrow Articles by Burroughs, K. D.
Right arrow Articles by Davis, B.
Right arrow Articles by Sowell, K.
Right arrow Articles by Everitt, J. I.
Right arrow Articles by Fuchs-Young, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of the Society for Gynecologic Investigation, Vol. 7, No. 4, 249-256 (2000)
DOI: 10.1177/107155760000700410

Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma

Cheryl Lyn Walker, PhD

University of Texas M. D. Anderson Cancer Center-Science Park, research Division, Smithville, Texas; the national Institute of Environmental Health Sciences, Research Triangle Park, North Carolina; Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina; cwalker{at}odin.mdacc.tmc.edu

Kevin D. Burroughs, PhD

Barbara Davis, VMD, PhD

Kalyn Sowell, BS

Jeffrey I. Everitt, DVM

Robin Fuchs-Young, PhD

University of Texas M. D. Anderson Cancer Center-Science Park, research Division, Smithville, Texas; the national Institute of Environmental Health Sciences, Research Triangle Park, North Carolina; Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina

Objective: Uterine leiomyoma are the most common gynecologic neoplasm and a primary cause of hysterectomy in premenopausal women. Preclinical studies were conducted in the Eker rat model to investigate the potential efficacy of selective estrogen receptor modulators (SERMs) as therapeutic agents for this tumor.

Methods: Twelve-month-old Eker rats were randomized into five treatment arms including tamoxifen, placebo, LY 326315, vehicle, and no treatment. Additional animals received ovariectomy or sham surgery at 4 months of age to determine the effect of ovarian ablation on tumor development. The study was terminated after 2 to 4 months of treatment, and tumor incidence, size, proliferative and apoptotic indices were determined. Size and incidence data were subjected to chi-square analysis. One-way analysis of variance and Fisher's least significant difference tests were used to compare proliferative and apoptotic indices.

Results: Ovariectomy virtually ablated leiomyoma development, indicating that these tumors were dependent on ovarian hormones for growth and development. Treatment with tamoxifen or raloxifene analog LY 326315 reduced leiomyoma incidence by 40-60% and reduced the size of remaining tumors. The effect of SERMs on leiomyomas was mediated by a decrease in cell proliferation without a decrease in apoptotic index.

Conclusion: SERMs have been shown to be therapeutically efficacious against breast cancer and to reduce tumor incidence in women at increased risk for this disease. The present data indicate that therapeutic efficacy may also be extended to uterine leiomyoma and demonstrate the utility of this animal model for preclinical studies to identify new therapeutic modalities.

Key Words: Tamoxifen • raloxifene • uterus • leiomyoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?